A Phase II, Open Label, Multiple Arm Study of Single Agent AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 30 Jul 2019
Price : $35 *
At a glance
- Drugs Alpelisib (Primary) ; Binimetinib (Primary) ; Capmatinib (Primary) ; Ceritinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 25 Jul 2019 Planned End Date changed from 1 Feb 2019 to 30 Sep 2019.
- 25 Jul 2019 Planned primary completion date changed from 1 Feb 2019 to 30 Sep 2019.
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer